AWHL files 8-K/A to fix warrant form termination date, adds Ex. 4.1

Rhea-AI Filing Summary

Aspira Women’s Health Inc. filed an amended Form 8-K to correct the form of its Amended and Restated Series A Common Stock Warrant. The company stated that the version previously included with its September 25, 2025 disclosure inadvertently listed an incorrect termination date. The corrected warrant form is filed as Exhibit 4.1 and incorporated by reference.

The amendment is reported under Item 1.01 (Entry into a Material Definitive Agreement), with Item 3.02 (Unregistered Sales of Equity Securities) incorporating Item 1.01 by reference. The earliest event date is September 19, 2025.

8-K Event Classification

3 items: 1.01, 3.02, 9.01

3 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 3.02 Unregistered Sales of Equity Securities Securities

The company sold equity securities in a private placement or other unregistered transaction.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 11/03/2025 - 04:16 PM Learn about SEC filing dates

FAQ

What did AWHL change in this 8-K/A?

The company corrected the form of its Amended and Restated Series A Common Stock Warrant to fix an incorrect termination date and filed the correct form as Exhibit 4.1.

Which items are referenced in the amendment for AWHL?

It is reported under Item 1.01, and Item 3.02 incorporates Item 1.01 by reference.

When was the earliest event date for AWHL’s amendment?

The earliest event date is September 19, 2025.

When did AWHL originally disclose the warrant amendments?

The prior disclosure occurred on September 25, 2025.

What exhibit contains the corrected warrant form for AWHL?

The corrected form is included as Exhibit 4.1.

What is AWHL’s trading symbol and market?

The trading symbol is AWHL on the OTC QX Market.

Who signed the AWHL amendment?

It was signed by Michael Buhle, Chief Executive Officer.

Aspira Women's Health Inc.0000926617false00009266172025-09-192025-09-19

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

(Amendment No. 1)

​

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 19, 2025

ASPIRA WOMEN’S HEALTH INC.

(Exact name of registrant as specified in its charter)

​

​	​	​	​	​
Delaware		001-34810		33-0595156
(State or other jurisdiction of	​	(Commission	​	(IRS Employer
incorporation or organization)	​	File Number)	​	Identification No.)

​

12117 Bee Caves Road, Building III, Suite 100

Austin, TX 78738

(Address of principal executive office) (Zip Code)

(512) 519-0400

(Registrants’ telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​	​
☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
​	​
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
​	​
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
​	​
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​	​	​
Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001	​	AWHL	​	OTC QX Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

Item 1.01 Entry into a Material Definitive Agreement.

​

Explanatory Note

​

On September 25, 2025, Aspira Women’s Health Inc. (the “Company”) disclosed that it had entered into certain amendments to its Amended and Restated Series A Common Stock Warrants.  The form of such warrant included with the original Form 8-K disclosure inadvertently included an incorrect termination date.  The correct form of warrant is attached hereto as Exhibit 4.1 and incorporated herein by reference.

​

Item 3.02 Unregistered Sales of Equity Securities.

The information in Item 1.01 is hereby incorporated herein by reference.

​

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

​	​	​
Exhibit No.		Description
4.1	​	Form of Amended and Restated Warrant
104	​	Cover Page Interactive Data File (embedded within the Inline XBRL document).

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: November 3, 2025

​

	ASPIRA WOMEN’S HEALTH INC.
	By:	/s/ Michael Buhle
	Name:	Michael Buhle
	Title:	Chief Executive Officer

​

​

​